CVKD

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. (CVKD) has 8 SEC Form 4 filings (16 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 2, 2026.

The most active filer is Chairman and CEO Pham Quang X with 16 filings. Insiders have net sold $283K over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Quang X. Pham
  • Employees:4
  • HQ:Ponte Vedra, FL, US
  • IPO:2023-01-20

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$283K

reported sales (SEC code S)

Unique Insiders

1

in the rolling window

Market Cap

$6.7M

latest known value

Source
Sale$22KJul 2SEC ↗
Sale$6KJun 27SEC ↗
Sale$28KJun 27SEC ↗
Sale$33KJun 24SEC ↗
Sale$7KJun 24SEC ↗
Sale$11KJun 18SEC ↗
Sale$2KJun 18SEC ↗
Sale$6KJun 16SEC ↗
Sale$51KJun 16SEC ↗
Sale$13KJun 16SEC ↗
Sale$26KJun 11SEC ↗
Sale$53KJun 11SEC ↗
Sale$15KJun 11SEC ↗
Sale$2KJun 3SEC ↗
Sale$2KJun 3SEC ↗
Pham Quang XFirst filing
Sale$7KMay 27SEC ↗

Related companies

Cadrenal Therapeutics, Inc. is in the Healthcare sector.